Abstract
| Original language | English |
|---|---|
| Article number | 179 |
| Pages (from-to) | 1-23 |
| Number of pages | 23 |
| Journal | BMC Medicine |
| Volume | 11 |
| DOIs | |
| Publication status | Published - 2013 |
| Externally published | Yes |
Fingerprint
Cite this
}
Personalizing health care: Feasibility and future implications. / Godman, Brian; Finlayson, Alexander; Cheema, Parneet; Zebedin-Brandl, Eva; Gutiérrez-Ibarluzea, Iñaki; Jones, Jan; Malmström, Rickard; Asola, Elina; Baumgärtel, Christoph; Bennie, Marion; Bishop, Iain; Bucsics, Anna; Campbell, Stephen; Diogene, Eduardo; Ferrairo, Alessandra; Fürst, Jurij; Garuoliene, Kristina; Gomes, Miguel ; Harris, Katharine; Haycox, Alan; Herholz, Harald; Hviding, Krystyna; Jan, Saira; Kalaba, Marija; Kvalheim, Christina; Laius, Ott; Lööv, Sven-Åke; Malinowska, Kamila; Martin, Andrew; McCullagh, Laura; Nilsson, Fredrik ; Paterson, Ken; Schwabe, Ulrich; Selke, Gisbert; Sermet, Catherine; Simoens, Steven; Tomek, Dominik; Vlahovic-Palcevski, Vera; Voncina, Luka; Wladysiuk, Magdalena; Van Woerkom, Menno; Wong-Rieger, Durhane; Zara, Corrine; Ali, Raghib; Gustafsson, Lars.
In: BMC Medicine, Vol. 11, 179, 2013, p. 1-23.Research output: Contribution to journal › Article
TY - JOUR
T1 - Personalizing health care: Feasibility and future implications
AU - Godman, Brian
AU - Finlayson, Alexander
AU - Cheema, Parneet
AU - Zebedin-Brandl, Eva
AU - Gutiérrez-Ibarluzea, Iñaki
AU - Jones, Jan
AU - Malmström, Rickard
AU - Asola, Elina
AU - Baumgärtel, Christoph
AU - Bennie, Marion
AU - Bishop, Iain
AU - Bucsics, Anna
AU - Campbell, Stephen
AU - Diogene, Eduardo
AU - Ferrairo, Alessandra
AU - Fürst, Jurij
AU - Garuoliene, Kristina
AU - Gomes, Miguel
AU - Harris, Katharine
AU - Haycox, Alan
AU - Herholz, Harald
AU - Hviding, Krystyna
AU - Jan, Saira
AU - Kalaba, Marija
AU - Kvalheim, Christina
AU - Laius, Ott
AU - Lööv, Sven-Åke
AU - Malinowska, Kamila
AU - Martin, Andrew
AU - McCullagh, Laura
AU - Nilsson, Fredrik
AU - Paterson, Ken
AU - Schwabe, Ulrich
AU - Selke, Gisbert
AU - Sermet, Catherine
AU - Simoens, Steven
AU - Tomek, Dominik
AU - Vlahovic-Palcevski, Vera
AU - Voncina, Luka
AU - Wladysiuk, Magdalena
AU - Van Woerkom, Menno
AU - Wong-Rieger, Durhane
AU - Zara, Corrine
AU - Ali, Raghib
AU - Gustafsson, Lars
PY - 2013
Y1 - 2013
N2 - Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer's perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients
AB - Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer's perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients
U2 - 10.1186/1741-7015-11-179
DO - 10.1186/1741-7015-11-179
M3 - Article
VL - 11
SP - 1
EP - 23
JO - BMC Medicine
JF - BMC Medicine
SN - 1741-7015
M1 - 179
ER -